Skip to main content
Top

28-09-2024 | Thalassemia | Original Article

Characterisation of β-thalassemia mutations in a tertiary care referral hospital in southern India- A descriptive study

Authors: Dheebika Kuppusamy, Angalena Ramachandran, Nivedita Nanda, Chinnaiah Govindareddy Delhi Kumar, Rakhee Kar

Published in: Indian Journal of Hematology and Blood Transfusion

Login to get access

Abstract

Purpose

Thalassemia is the most prevalent autosomal single-gene disorder. More than 250 mutations that impact β-globin gene expression levels through diverse mechanisms are known to cause β-thalassemia. Regional variations in β-thalassemia mutations are common. This study was undertaken to study the common β-thalassemia mutations in a tertiary care hospital in Puducherry, southern India.

Methods

The study was conducted over two years (2020–2021). Patients with β-thalassemia, their carrier parents and siblings, mainly from Puducherry and various districts of Tamil Nadu, were included to screen prevalent mutations. The genomic DNA isolated from whole blood samples was hybridized using a strip assay kit by reverse dot blot hybridization. For a few samples, DNA sequencing was done from a referral lab.

Results

Among the 92 cases, comprising 40 index cases and 52 family members, IVS I-5(G > C) was the most common mutation detected, accounting for 78%, followed by Cd 15(G > A) at 5.3% of all mutant alleles. Additional β-thalassemia mutations identified included − 28 (A > G) and Poly A site (T > C) through sequencing, along with FS Cd 41/42 (-TCTT) and Cd 8/9 (+ G) detected via strip assay. One index case of Sickle-β thalassemia with IVS I-5(G > C) + Cd 6(A > T) and another case of HbE-β thalassemia with Cd8/9(+ G) + Cd 26(G > A) mutant alleles was also identified. Uncharacterized mutant alleles in the study accounted for 4.5%.

Conclusion

This study helped us to identify the common mutation patterns in our hospital population. Additional mutations could be detected by sequencing beyond those identified through strip assay. Mutation screening plays a crucial role in genetic counselling and prenatal diagnosis.
Literature
5.
go back to reference Muncie HL Jr, Campbell J (2009) Alpha and beta thalassemia. Am Fam Physician 80(4):339–344PubMed Muncie HL Jr, Campbell J (2009) Alpha and beta thalassemia. Am Fam Physician 80(4):339–344PubMed
8.
go back to reference Nadkarni AH, Gorakshakar AC, Sawant PM, Italia KY, Upadhye DS, Gorivale MS, Mehta PR, Hariharan P, Ghosh K, Colah RB (2019) The phenotypic and molecular diversity of hemoglobinopathies in India: a review of 15 years at a referral center. Int J Lab Hematol 41(2):218–226. https://doi.org/10.1111/ijlh.12948CrossRefPubMed Nadkarni AH, Gorakshakar AC, Sawant PM, Italia KY, Upadhye DS, Gorivale MS, Mehta PR, Hariharan P, Ghosh K, Colah RB (2019) The phenotypic and molecular diversity of hemoglobinopathies in India: a review of 15 years at a referral center. Int J Lab Hematol 41(2):218–226. https://​doi.​org/​10.​1111/​ijlh.​12948CrossRefPubMed
17.
Metadata
Title
Characterisation of β-thalassemia mutations in a tertiary care referral hospital in southern India- A descriptive study
Authors
Dheebika Kuppusamy
Angalena Ramachandran
Nivedita Nanda
Chinnaiah Govindareddy Delhi Kumar
Rakhee Kar
Publication date
28-09-2024
Publisher
Springer India
Keyword
Thalassemia
Published in
Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-024-01886-9

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now